Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Loratadine Sales Keep Perrigo On Track To Meet Core Business Growth Goals

This article was originally published in The Tan Sheet

Executive Summary

Perrigo expects to meet its fiscal 2004 target for core business growth despite continued delays in the approval of its 10 mg loratadine tablets (Schering-Plough's Claritin)
Advertisement

Related Content

Leiner Looks To Rule Claritin Equivalent Market With Summer Launches
Leiner Looks To Rule Claritin Equivalent Market With Summer Launches
Leiner Looks To Rule Claritin Equivalent Market With Summer Launches
Perrigo’s Generic Loratadine Offerings Could Boost Firm’s Cough/Cold Sales
Perrigo’s Generic Loratadine Offerings Could Boost Firm’s Cough/Cold Sales
Perrigo Nets Former Pharmacia Counsel Kingma To Support New Strategy

Topics

Advertisement
UsernamePublicRestriction

Register

PS096456

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel